局限期前列腺癌雄激素剥夺联合放疗后睾酮恢复的列线图
研究纳入2个学术医疗中心2011年1月至2016年10月连续接受ADT-RT且基线睾酮已知的局限期前列腺癌患者340例,用Kaplan-Meier和Cox模型分析睾酮恢复预测因素,并在外部中心验证列线图。结果显示ADT持续时间短、基线睾酮高和BMI低与睾酮恢复较快相关,验证队列一致性指数为0.71(95%CI 0.64-0.78)。
要点
- 340例中69.7%接受短程ADT(中位6个月),30.3%接受长程ADT(中位24.3个月)。
- 睾酮恢复中位时间短程ADT为17.2个月,长程ADT为24.0个月(P=0.004)。
- 验证队列列线图预测1、2、3年睾酮恢复概率的一致性指数为0.71(95%CI 0.64-0.78)。
核心结论
- 在局限期前列腺癌患者中,ADT-RT后睾酮恢复情况存在差异。
- 利用基线睾酮、ADT持续时间、BMI、年龄和种族构建的列线图可估计睾酮恢复的可能性。
研究设计与样本
- 研究为在2个学术医疗中心连续纳入2011年1月至2016年10月接受ADT-RT且基线睾酮已知的局限期前列腺癌患者340例。
- 睾酮恢复定义为末次ADT注射至睾酮恢复正常的时间,采用Kaplan-Meier法估计恢复时间,Cox比例风险模型筛选预测因素。
- 列线图在中心1训练并在中心2进行外部验证。
主要发现
- 340例患者中69.7%接受短程ADT(中位持续时间6个月),30.3%接受长程ADT(中位持续时间24.3个月),中位随访26.7个月。
- 睾酮恢复中位时间短程ADT为17.2个月,长程ADT为24.0个月(P=0.004)。
- 2年睾酮恢复累积发生率长程ADT为53.1%,短程ADT为65.7%(P=0.004)。
- 多因素分析中,ADT持续时间较短(HR 0.96,P=0.004)、基线睾酮较高(HR 1.004,P<0.001)和BMI较低(HR 0.95,P=0.002)与睾酮恢复时间较短相关。
- 年龄较大(HR 0.97,P=0.09)和白种人(HR 0.67,P=0.06)呈现为睾酮恢复时间较长的趋势预测因素。
关键数值与推荐
- 列线图用于预测1年、2年和3年睾酮恢复概率。
- 验证队列一致性指数为0.71(95%CI 0.64-0.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Testosterone recovery (TR) after androgen deprivation therapy (ADT) and radiation therapy (RT) is not well characterized. We studied TR in men who received RT and either short-term ADT (STADT) or long-term ADT (LTADT) and aimed to create a nomogram to predict TR. METHODS AND MATERIALS: We identified consecutive localized prostate cancer patients treated with ADT-RT at 2 academic medical centers from January 2011 to October 2016 with documented baseline testosterone. TR was time from last ADT injection to testosterone normalization. The Kaplan-Meier method was used to estimate time to TR. Cox proportional hazards models identified TR predictors. A nomogram was trained with site 1 and externally validated with site 2. RESULTS: A total of 340 patients were included; 69.7% received STADT for a median duration of 6 months; 30.3% received LTADT for a median duration of 24.3 months. Median follow-up was 26.7 months. Median time for TR was 17.2 months for STADT and 24.0 months for LTADT patients (P = .004). The 2-year cumulative incidence of TR was 53.1% after LTADT versus 65.7% after STADT (P = .004). On multivariate analysis, shorter duration ADT (hazard ratio [HR], 0.96; P = .004), higher pretreatment testosterone (HR, 1.004; P < .001), and lower body mass index (HR, 0.95; P = .002) were associated with shorter time to TR. Older age (HR, 0.97; P = .09) and white race (HR, 0.67; P = .06) trended as longer TR predictors. A nomogram was generated to predict probability of TR at 1, 2, and 3 years. The concordance index was 0.71 (95% confidence interval, 0.64-0.78) for the validation cohort. CONCLUSIONS: In this population of localized prostate cancer patients, TR after ADT-RT was variable. Using baseline testosterone, ADT duration, body mass index, age, and race, a predictive nomogram can estimate the likelihood of TR.
引用
- Spiegel DY, Hong JC, Oyekunle T, et al. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30419308. doi:10.1016/j.ijrobp.2018.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。